Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TSC2 mutant |
| Therapy | Irinotecan + Temozolomide + Temsirolimus |
| Indication/Tumor Type | osteosarcoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TSC2 mutant | osteosarcoma | no benefit | Irinotecan + Temozolomide + Temsirolimus | Case Reports/Case Series | Actionable | In a clinical case study, Torisel (temsirolimus), Temodar (temozolomide), and Camptosar (irinotecan) combination treatment resulted in progressive disease in a pediatric patient with osteosarcoma harboring a TSC2 mutation (PMID: 37523146; NCT03336931). | 37523146 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37523146) | High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer. | Full reference... |